tiprankstipranks
Pharvaris N.V. (DE:9EN)
NASDAQ:9EN
Germany Market
9EN
Pharvaris
RESEARCH TOOLSreports

Pharvaris (9EN) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

9EN Analyst Ratings

Strong Buy
9Ratings
Strong Buy
8 Buy
1 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Pharvaris
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

9EN Stock 12 Month Forecast

Average Price Target

€42.29
▲(42.38% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Pharvaris in the last 3 months. The average price target is €42.29 with a high forecast of €52.02 and a low forecast of €32.94. The average price target represents a 42.38% change from the last price of €29.70.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"€16","53":"€53","25.25":"€25.3","34.5":"€34.5","43.75":"€43.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":52.015785,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€52.02</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.28690669444445,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€42.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.9433305,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€32.94</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,25.25,34.5,43.75,53],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.15,29.985829615384613,31.821659230769228,33.657488846153846,35.493318461538465,37.329148076923076,39.164977692307694,41.00080730769231,42.836636923076924,44.672466538461535,46.50829615384615,48.34412576923077,50.17995538461538,{"y":52.015785,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.15,29.23745436111111,30.324908722222222,31.412363083333332,32.499817444444446,33.58727180555556,34.674726166666666,35.76218052777778,36.849634888888886,37.93708925,39.02454361111111,40.11199797222223,41.19945233333333,{"y":42.28690669444445,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.15,28.51871773076923,28.88743546153846,29.256153192307693,29.624870923076923,29.993588653846153,30.362306384615383,30.731024115384617,31.099741846153847,31.468459576923077,31.837177307692308,32.20589503846154,32.57461276923077,{"y":32.9433305,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.8,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.4,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.3,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.15,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€52.02Average Price Target€42.29Lowest Price Target€32.94
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:9EN
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
€52.02
Buy
75.14%
Upside
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Pharvaris (NASDAQ: PHVS), Caribou Biosciences (NASDAQ: CRBU) and Aveanna Healthcare Holdings (NASDAQ: AVAH)
Oppenheimer Analyst forecast on DE:9EN
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
€43.35
Buy
45.95%
Upside
Reiterated
08/13/26
Oppenheimer Remains a Buy on Pharvaris (PHVS)
Morgan Stanley Analyst forecast on DE:9EN
Maxwell Skor
Morgan Stanley
Morgan Stanley
€39.88
Buy
34.27%
Upside
Assigned
08/13/26
Morgan Stanley Sticks to Its Buy Rating for Pharvaris (PHVS)
Wells Fargo Analyst forecast on DE:9EN
Yanan Zhu
Wells Fargo
Wells Fargo
€47.68
Buy
60.54%
Upside
Assigned
08/13/26
Wells Fargo Issues a Buy Rating on Pharvaris (PHVS)
Guggenheim Analyst forecast on DE:9EN
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
€33.81→€34.68
Buy
16.76%
Upside
Reiterated
08/12/26
Guggenheim Remains a Buy on Pharvaris (PHVS)
Bank of America Securities Analyst forecast on DE:9EN
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
€30.34→€32.94
Hold
10.92%
Upside
Reiterated
08/12/26
Pharvaris (PHVS) Gets a Hold from Bank of America Securities
RBC Capital Analyst forecast on DE:9EN
Nevin Varghese
RBC Capital
RBC Capital
€44.21→€45.08
Buy
51.79%
Upside
Assigned
08/12/26
RBC Capital Reaffirms Their Buy Rating on Pharvaris (PHVS)
Cantor Fitzgerald Analyst forecast on DE:9EN
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
€39.88
Buy
34.27%
Upside
Reiterated
06/29/26
Cantor Fitzgerald Reaffirms Their Buy Rating on Pharvaris (PHVS)
JonesTrading Analyst forecast on DE:9EN
Debanjana Chatterjee
JonesTrading
JonesTrading
€45.08
Buy
51.79%
Upside
Reiterated
06/11/26
Buy Rating Reiterated on Pharvaris with Unchanged $52 Price Target Ahead of Key Phase 3 Deucrictibant XR Readout
Citizens JMP Analyst forecast on DE:9EN
Jonathan Wolleben
Citizens JMP
Citizens JMP
€65.02→€64.15
Buy
116.00%
Upside
Reiterated
05/13/26
Pharvaris price target lowered to $74 from $75 at CitizensPharvaris price target lowered to $74 from $75 at Citizens
Wedbush Analyst forecast on DE:9EN
Laura Chico
Wedbush
Wedbush
€36.41
Buy
22.60%
Upside
Reiterated
05/13/26
Analysts Are Bullish on Top Healthcare Stocks: Kura Oncology (KURA), Pharvaris (PHVS)
Wolfe Research Analyst forecast on DE:9EN
Andy Chen
Wolfe Research
Wolfe Research
€36.41
Buy
22.60%
Upside
Initiated
04/08/26
Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL) and Pharvaris (NASDAQ: PHVS)
Leerink Partners Analyst forecast on DE:9EN
Joseph Schwartz
Leerink Partners
Leerink Partners
€32.94
Buy
10.92%
Upside
Reiterated
01/13/26
Pharvaris (PHVS) Receives a Buy from Leerink Partners
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:9EN
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
€52.02
Buy
75.14%
Upside
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Pharvaris (NASDAQ: PHVS), Caribou Biosciences (NASDAQ: CRBU) and Aveanna Healthcare Holdings (NASDAQ: AVAH)
Oppenheimer Analyst forecast on DE:9EN
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
€43.35
Buy
45.95%
Upside
Reiterated
08/13/26
Oppenheimer Remains a Buy on Pharvaris (PHVS)
Morgan Stanley Analyst forecast on DE:9EN
Maxwell Skor
Morgan Stanley
Morgan Stanley
€39.88
Buy
34.27%
Upside
Assigned
08/13/26
Morgan Stanley Sticks to Its Buy Rating for Pharvaris (PHVS)
Wells Fargo Analyst forecast on DE:9EN
Yanan Zhu
Wells Fargo
Wells Fargo
€47.68
Buy
60.54%
Upside
Assigned
08/13/26
Wells Fargo Issues a Buy Rating on Pharvaris (PHVS)
Guggenheim Analyst forecast on DE:9EN
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
€33.81→€34.68
Buy
16.76%
Upside
Reiterated
08/12/26
Guggenheim Remains a Buy on Pharvaris (PHVS)
Bank of America Securities Analyst forecast on DE:9EN
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
€30.34→€32.94
Hold
10.92%
Upside
Reiterated
08/12/26
Pharvaris (PHVS) Gets a Hold from Bank of America Securities
RBC Capital Analyst forecast on DE:9EN
Nevin Varghese
RBC Capital
RBC Capital
€44.21→€45.08
Buy
51.79%
Upside
Assigned
08/12/26
RBC Capital Reaffirms Their Buy Rating on Pharvaris (PHVS)
Cantor Fitzgerald Analyst forecast on DE:9EN
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
€39.88
Buy
34.27%
Upside
Reiterated
06/29/26
Cantor Fitzgerald Reaffirms Their Buy Rating on Pharvaris (PHVS)
JonesTrading Analyst forecast on DE:9EN
Debanjana Chatterjee
JonesTrading
JonesTrading
€45.08
Buy
51.79%
Upside
Reiterated
06/11/26
Buy Rating Reiterated on Pharvaris with Unchanged $52 Price Target Ahead of Key Phase 3 Deucrictibant XR Readout
Citizens JMP Analyst forecast on DE:9EN
Jonathan Wolleben
Citizens JMP
Citizens JMP
€65.02→€64.15
Buy
116.00%
Upside
Reiterated
05/13/26
Pharvaris price target lowered to $74 from $75 at CitizensPharvaris price target lowered to $74 from $75 at Citizens
Wedbush Analyst forecast on DE:9EN
Laura Chico
Wedbush
Wedbush
€36.41
Buy
22.60%
Upside
Reiterated
05/13/26
Analysts Are Bullish on Top Healthcare Stocks: Kura Oncology (KURA), Pharvaris (PHVS)
Wolfe Research Analyst forecast on DE:9EN
Andy Chen
Wolfe Research
Wolfe Research
€36.41
Buy
22.60%
Upside
Initiated
04/08/26
Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL) and Pharvaris (NASDAQ: PHVS)
Leerink Partners Analyst forecast on DE:9EN
Joseph Schwartz
Leerink Partners
Leerink Partners
€32.94
Buy
10.92%
Upside
Reiterated
01/13/26
Pharvaris (PHVS) Receives a Buy from Leerink Partners
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
GHRSGH Research
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pharvaris

3 Months
Debanjana ChatterjeeJonesTrading
Success Rate
11/13 ratings generated profit
85%
Average Return
+19.76%
Copying Debanjana Chatterjee's trades and holding each position for 3 Months would result in 84.62% of your transactions generating a profit, with an average return of +19.76% per trade.
1 Year
Debanjana ChatterjeeJonesTrading
Success Rate
13/13 ratings generated profit
100%
Average Return
+49.38%
Copying Debanjana Chatterjee's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +49.38% per trade.
2 Years
Debanjana ChatterjeeJonesTrading
Success Rate
13/13 ratings generated profit
100%
Average Return
+58.43%
Copying Debanjana Chatterjee's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +58.43% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

9EN Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
14
16
13
8
5
Buy
4
5
8
6
9
Hold
0
2
2
3
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
23
23
17
16
In the current month, 9EN has received 14 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 9EN average Analyst price target in the past 3 months is 42.29.
Each month's total comprises the sum of three months' worth of ratings.

9EN Financial Forecast

9EN Earnings Forecast

Next quarter’s earnings estimate for 9EN is -€0.71 with a range of -€0.80 to -€0.64. The previous quarter’s EPS was -€0.70. 9EN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 9EN has Performed in-line its overall industry.
Next quarter’s earnings estimate for 9EN is -€0.71 with a range of -€0.80 to -€0.64. The previous quarter’s EPS was -€0.70. 9EN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 9EN has Performed in-line its overall industry.
No data currently available

9EN Sales Forecast

Next quarter’s sales forecast for 9EN is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 9EN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 9EN has Performed in-line its overall industry.
Next quarter’s sales forecast for 9EN is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 9EN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 9EN has Performed in-line its overall industry.

9EN Stock Forecast FAQ

What is DE:9EN’s average 12-month price target, according to analysts?
Based on analyst ratings, Pharvaris N.V.’s 12-month average price target is 42.29.
    What is DE:9EN’s upside potential, based on the analysts’ average price target?
    Pharvaris N.V. has 42.38% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Pharvaris N.V. a Buy, Sell or Hold?
          Pharvaris N.V. has a consensus rating of Strong Buy, which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Pharvaris N.V.’s share price target?
            The average share price target for Pharvaris N.V. is 42.29. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €52.02 ,and the lowest forecast is €32.94. The average share price target represents 42.38% Increase from the current price of €29.7.
              What do analysts say about Pharvaris N.V.?
              Pharvaris N.V.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of Pharvaris N.V.?
                To buy shares of DE:9EN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.